Max Healthcare Institute (MAXHEALTH) Weekly Analysis
Price & Volume
The stock price rose by 5.7% during the week, ending at 1007.65. This upward movement occurred alongside a weekly price range of 5.88%. The stock is currently trading slightly above its 50-day moving average, which represents the average closing price over the last 50 days.
Technicals
This week, the stock price closed at 1007.65, marking a 5.70% increase. The Relative Strength Index (RSI), which measures the speed and change of price movements to identify overbought or oversold conditions, rose to 57.99. The Moving Average Convergence Divergence (MACD), a tool that shows the relationship between two price averages to identify momentum, shows a positive histogram of 8.59. Bollinger Band width, which tracks volatility or the degree of price variation, decreased to 8.26%. Overall, the asset shows improving momentum while remaining below its primary moving averages.
Fundamentals
Max Healthcare Institute has demonstrated consistent expansion, with revenue growing at a 3-year CAGR of 21.3% (the annual rate of growth over three years). In the most recent fiscal year ending March 2025, revenue reached ₹7,028, reflecting a 30.0% YoY increase. Profitability remains a focus, with net profit at ₹1,076 and a TTM (trailing twelve-month, the last 12 months of data) net profit margin of 17.4%. The company maintains a solid cash position, with cash flow from operations (CFO, cash generated from core business activities) at ₹1,459 as of March 2025. The current valuation stands at 139.2× PE (price-to-earnings ratio, the share price relative to earnings per share) and 11.5× PB (price-to-book ratio, the share price relative to book value).
News
During the week of April 13, 2026, to April 19, 2026, Max Healthcare Institute experienced notable market activity. On April 14, 2026, reports indicated that mutual funds increased their holdings in the company by over one crore shares during March 2026. Subsequently, on April 15, 2026, the stock price surged 3.34% to reach a daily high of Rs 986.55, outperforming its sector by 2.55 percentage points. By April 16, 2026, the company was identified as one of eight stocks exhibiting a bullish Relative Strength Index (RSI) upswing. These developments occurred against a broader backdrop of healthcare sector growth projections and ongoing investor interest ahead of the fourth-quarter earnings results.
Events
Max Healthcare Institute Limited has initiated a postal ballot process to seek shareholder approval for the re-appointment of Mr. Narayan K. Seshadri as a Non-Executive and Non-Independent Director. Voting is conducted exclusively through remote e-voting, which remains open from April 12, 2026, until May 11, 2026.
Max Healthcare Institute Limited has initiated a postal ballot to seek shareholder approval via remote e-voting for the re-appointment of Mr. Narayan K. Seshadri as a Non-Executive and Non-Independent Director for a three-year term starting May 16, 2026.
Max Healthcare has entered into an agreement to acquire a 58.39% controlling stake in Bhubaneswar-based Kalinga Hospital Ltd. for ₹300 crore to expand its footprint in Eastern India. Additionally, the board approved the re-appointment of Mr. Narayan K. Seshadri as a non-executive director for a three-year term.
Max Healthcare Institute has approved the acquisition of a 58.39% controlling stake in Bhubaneswar-based Kalinga Hospital Ltd for ₹300 crore to expand its footprint in Eastern India. Additionally, the Board approved the re-appointment of Mr. Narayan K. Seshadri as a Non-Executive and Non-Independent Director for a three-year term.
Max Healthcare has entered into an agreement to acquire a 58.39% controlling stake in Bhubaneswar-based Kalinga Hospital for ₹300 crore to expand its footprint in Eastern India. Additionally, the board approved the re-appointment of Mr. Narayan K. Seshadri as a Non-Executive Director for a three-year term.
Max Healthcare Institute Limited has initiated a postal ballot to seek shareholder approval via remote e-voting for the re-appointment of Mr. Narayan K. Seshadri as a Non-Executive and Non-Independent Director for a three-year term starting May 16, 2026.
Max Healthcare has entered into an agreement to acquire a 58.39% controlling stake in Bhubaneswar-based Kalinga Hospital Ltd. for ₹300 crore to expand its footprint in Eastern India. Additionally, the board approved the re-appointment of Mr. Narayan K. Seshadri as a non-executive director for a three-year term.
Max Healthcare Institute has approved the acquisition of a 58.39% controlling stake in Bhubaneswar-based Kalinga Hospital Ltd for ₹300 crore to expand its footprint in Eastern India. Additionally, the Board approved the re-appointment of Mr. Narayan K. Seshadri as a Non-Executive and Non-Independent Director for a three-year term.
Max Healthcare has entered into an agreement to acquire a 58.39% controlling stake in Bhubaneswar-based Kalinga Hospital for ₹300 crore to expand its footprint in Eastern India. Additionally, the board approved the re-appointment of Mr. Narayan K. Seshadri as a Non-Executive Director for a three-year term.
Weekly Snapshot
Highlights
- The stock price rose by 5.7% this week, closing at 1007.65.
- The Relative Strength Index (RSI), which measures the speed and change of price movements to identify overbought or oversold conditions, rose to 57.99.
- Max Healthcare Institute announced an agreement to acquire a 58.39% controlling stake in Kalinga Hospital for 300 crore.
- Reports indicated that mutual funds increased their holdings in the company by over one crore shares during March 2026.
- The company maintains a solid cash position, with cash flow from operations at 1,459 as of March 2025.
What This Means
Max Healthcare experienced a positive week with a 5.7% price increase and improved momentum indicators. The company is expanding its footprint in Eastern India through the acquisition of a controlling stake in Kalinga Hospital. Technical indicators show strengthening momentum, while institutional interest remains evident through increased mutual fund holdings.
Latest Quarter Info
For the quarter ending December 2025, the company demonstrated a mixed financial performance characterized by strong year-over-year growth offset by sequential contraction. While revenue and net profit grew by 10.7% and 25.9% respectively on a year-over-year basis, both metrics declined quarter-over-quarter, with net profit experiencing a significant 38.7% reduction. The operating margin remained stable at 26%, reflecting consistent operational efficiency despite the top-line volatility. Profitability was further impacted by interest and depreciation costs, resulting in a net profit of 301.0. The divergence between the solid annual expansion and the recent quarterly pullback highlights a period of adjustment in the company's earnings trajectory, as the business navigates current operational expenses and tax obligations.